Monoclonal Anti-Porcine CD8a, Clone 76-2-11 (produced *in vitro*)

Catalog No. NR-28540

This reagent is the tangible property of the U.S. Government.

For research use only. Not for human use.

Contributor:

Joan K. Lunney, Ph.D., Animal Parasitic Diseases Laboratory, Beltsville Agricultural Research Center, Agricultural Research Service, USDA, Beltsville, MD

Maunfacturer:

BEI Resources

Product Description:

Antibody Class: IgG2aκ

Mouse monoclonal antibody prepared against porcine CD8a was purified from clone 76-2-11 hybridoma supernatant by protein G affinity chromatography. The B cell hybridoma was generated by the fusion of Sp2/0-Ag14 mouse myeloma cells with splenocytes from BALB/c mice that had been immunized with thymocytes from dd miniature swine.[1] Clone 76-2-11 was shown to block, and with complement to eliminate, porcine CTL effectors and precursors,[2] and was assigned as the prototype anti-CD8a monoclonal antibody at the First and Second International Swine CD Workshops.[3-6]

Material Provided:

Each vial of NR-28540 contains approximately 100 µL of purified monoclonal antibody in PBS. The concentration, expressed as mg per mL, is shown on the Certificate of Analysis.

Packaging/Storage:

NR-28540 was packaged aseptically in screw-capped plastic vials and is provided frozen on dry ice. NR-28540 should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Functional Activity:

NR-28540 is reported to be cytotoxic, to function in flow cytometry assays, and to immunoprecipitate a 32 kilodalton protein expressed by porcine cytotoxic T cells.[1-6]

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-Porcine CD8a, Clone 76-2-11 (produced *in vitro*), NR-28540."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Pescovitz, M. D., et al., "Preparation and Characterization of Monoclonal Antibodies Reactive with Porcine PBL." J. Immunol. 133 (1984): 368-375. PubMed: 6609988.
2. Pescovitz, M. D., et al., "Murine Anti-Swine T4 and T8 Monoclonal Antibodies: Distribution and Effects on Proliferative and Cytotoxic T Cells." J. Immunol. 134 (1985): 37-44. PubMed: 3871107.
3. Lunney, J. K., et al. "Overview of the First International Workshop to Define Swine Leukocyte Cluster of Differentiation (CD) Antigens." Vet. Immunol. Immunopathol. 43 (1994): 193-206. PubMed: 7856053.

4. Saalmüller, A., et al. “Analyses of mAb Reactive with Porcine CD8.” Vet. Immunol. Immunopathol. 43 (1994): 249-254. PubMed: 7531908.
5. Saalmüller, A., et al. “Overview of the Second International Workshop to Define Swine Cluster of Differentiation (CD) Antigens.” Vet. Immunol. Immunopathol. 60 (1998): 207-228. PubMed: 9589560.
6. Zuckermann, F. A., et al. “Report on the Analyses of mAb Reactive with Porcine CD8 for the Second International Swine CD Workshop.” Vet. Immunol. Immunopathol. 60 (1998): 291-303. PubMed: 9589568.

Support Provided by NIAID

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898